NRX Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on June 8, 2022, covering events occurring on June 6, 2022. NRX Pharmaceuticals, Inc. (NRXP) is a Delaware corporation and an emerging growth company. The filing primarily addresses the appointment of a new Chief Financial Officer and Treasurer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. As a current report focused on corporate governance, it contains no financial statement data for the period.
Material Changes
The material change reported is the appointment of Dr. Seth Van Voorhees as Chief Financial Officer and Treasurer, effective June 13, 2022. Dr. Van Voorhees brings prior experience as CFO for PDS Biotechnology Corporation, Research Frontiers Inc., and American Pacific Corp., along with investment banking experience at Merrill Lynch, UBS Warburg, and Wasserstein Perella.
Employment Arrangements and Compensation
- Base Salary: Approximately $400,000 annually ($33,333.33 monthly).
- Target Bonus: $200,000 annually, subject to Board discretion and performance.
- Equity Grant: Options to purchase 325,000 shares of common stock at the closing price on the effective date, vesting over two years.
- Severance: In the event of termination without "cause," change of control, or resignation for "good reason," Dr. Van Voorhees is entitled to nine months of base salary, a prorated target bonus, and full acceleration of unvested options.
Outlook, Risks, and Contingencies
The filing does not contain updated business guidance, risk factors, or contingencies beyond the standard disclosure that the employment agreement summary is subject to the full terms of the agreement, which will be filed as an exhibit to a future periodic report.
Key Facts for Investor Verification
- Verify the effective date of Dr. Van Voorhees' employment (June 13, 2022) and the start of his compensation.
- Review the full employment agreement when filed as an exhibit to a periodic report for detailed terms.
- Monitor the vesting schedule of the 325,000 stock options granted.
- Confirm the exercise price of the options based on the closing stock price on June 13, 2022.